Syngene International Expands Capabilities
Syngene International, a global contract research, development and manufacturing organization (CRDMO), announces plans to add a GMP bioconjugation suite.
This new capability will enable Syngene to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.
- Complement commercial payload, linker and monoclonal antibodies services
- Provide fully integrated services for ADCs
Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing
Syngene International is a global CRDMO based in Bengaluru, India.
Author summary: Syngene International expands ADC services.
More News
- 🚨 La santé de Bruce Willis, 70 ans, est en train de décliner
- Cardinals vs. Buccaneers Final Score Prediction for NFL Week 13
- Jakarta's growth, Louvre fees, Brazilian soaps global rise
- Saudi Arabia becomes the new strategic front line as US navigates regional rivalries
- £3.53 for The Traitors? The BBC licence fee is a bargain
- Stoke City vs Hull City; Sky Bet Championship
- Stoke City 1-0 Hull City: Live Match Updates and Key Moments
- Opinion - When Puerto Rico was offered independence — and one man turned it down
- Championship: Sheff Utd lead Leicester 3-0
- Paris Best Restaurants Guide 2026 (Top 15) – curated picks for dining in the city